光生物调节治疗中期干性年龄相关性黄斑变性的成本效果分析
基于LIGHTSITE III 24个月试验数据,采用5状态Markov模型评估光生物调节(PBM)治疗双侧中期干性AMD的成本效果。结果显示PBM在10年 horizon内增量成本29,556美元、获得5.244个QALY,ICER为73,910美元/QALY,低于美国10万和15万美元的支付意愿阈值。
要点
- PBM治疗中期干性AMD的ICER为73,910美元/QALY,低于10万和15万美元阈值。
- 成本效果主要由24个月地图状萎缩(GA)发生率相对降低71.7%驱动。
核心结论
- 从美国医疗支付方视角,PBM治疗中期干性AMD在常规支付意愿阈值下具有成本效果。
研究设计与样本
- 基于LIGHTSITE III 24个月试验数据的模型化成本效果分析,采用5状态Markov模型、6个月周期、10年 horizon,成本和结局年贴现率3%。
- 模拟队列为双侧中期干性AMD且最佳矫正视力(BCVA)20/32-20/100的成人,符合LIGHTSITE III入组标准。
主要发现
- PBM组10年获得5.244个贴现QALY,增量成本29,556美元,基础案例ICER为73,910美元/QALY。
- ICER在临床现实场景中 ranging from 36,700美元/QALY(每疗程1,000美元)至117,694美元/QALY(GA减少30%)。
- 仅每疗程5,000美元场景同时超过10万和15万美元支付意愿阈值。
关键数值与推荐
- 基础案例ICER 73,910美元/QALY低于美国100,000美元和150,000美元支付意愿阈值。
- 24个月地图状萎缩(GA)发生率相对降低71.7%。
临床怎么用
- 结果为PBM用于中期干性AMD的医保覆盖考量提供支持,但需等待GA减少的独立重复验证和前瞻性EQ-5D数据收集。
局限性
- 需独立重复验证GA减少效果,并需前瞻性收集EQ-5D数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the cost-effectiveness of photobiomodulation (PBM) for intermediate dry age-related macular degeneration (AMD) from the US healthcare payer perspective, using 24-month LIGHTSITE III trial data. DESIGN: Model-based cost-effectiveness analysis using a 5-state Markov model with 6-month cycles over a 10-year horizon, discounting costs and outcomes at 3% annually. PARTICIPANTS: Modeled cohort of adults with bilateral intermediate dry AMD and best-corrected visual acuity (BCVA) 20/32-20/100, consistent with LIGHTSITE III eligibility. METHODS: Transition probabilities were derived from LIGHTSITE III 24-month outcomes and AREDS natural history data. Costs were derived from 2025 Medicare Physician Fee Schedule and published claims-based sources. One-way and probabilistic sensitivity analyses, a societal perspective, a 2-year limited treatment scenario, and a 5-year national budget impact analysis were conducted. MAIN OUTCOME MEASURES: Quality-adjusted life-years (QALYs) derived from published visual acuity-to-utility mapping and VFQ-25-to-EQ-5D conversion of LIGHTSITE III quality-of-life data; incremental cost-effectiveness ratio (ICER) as cost per QALY; 5-year national budget impact. RESULTS: PBM yielded 5.244 discounted QALYs at an incremental cost of $29,556 over 10 years, producing a base-case ICER of $73,910 per QALY, below both the $100,000 and $150,000 US willingness-to-pay thresholds. The ICER ranged from $36,700 ($1,000/course) to $117,694 per QALY (30% geographic atrophy [GA] reduction) across clinically realistic scenarios. Only the $5,000/course scenario exceeded both thresholds. The 5-year cumulative national budget impact was $25.0 billion at 20% uptake. CONCLUSIONS: PBM is cost-effective at conventional US willingness-to-pay thresholds, driven primarily by a 71.7% relative reduction in incident GA at 24 months. These findings support coverage consideration of PBM for intermediate dry AMD, pending independent replication of the GA reduction and prospective EQ-5D data collection.
引用
- Watane A, Witkin A, Heier J, et al. Cost-Effectiveness of Photobiomodulation for Intermediate Dry Age-Related Macular Degeneration: A Model-Based Analysis Using the LIGHTSITE III 24-Month Trial. Am J Ophthalmol. 2026. PMID: 42501959. doi:10.1016/j.ajo.2026.07.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。